UCB Unveils 4-Year BIMZELX® (bimekizumab-bkzx) Data for Moderate-to-Severe Plaque Psoriasis at EADV 2024.

Merck Updates Phase 3 KEYFORM-007 Trial on Experimental Fixed-Dose Favezelimab and Pembrolizumab Combo for PD-L1 Positive Metastatic Colorectal Cancer Post-Treatment.

Recent data reveal that Almirall’s EBGLYSS® (Lebrikizumab) maintained long-term disease control for up to three years in over 80% of adults and adolescents with moderate-to-severe atopic dermatitis.

Halia Therapeutics Unveils Encouraging Preclinical Obesity Results: HT-6184 with Semaglutide Boosts Weight Reduction and Maintains Lean Muscle.

These results indicate the effectiveness of troriluzole in changing the f-SARA score from baseline after three years of therapy.

Kazia Therapeutics Reports EVT801 Clinical Findings at 15th Biennial Ovarian Cancer Research Conference.

Arrowhead Pharmaceuticals Seeks Approval to Start Phase 1/2a Trial of ARO-INHBE for Obesity Treatment.

Final Overall Survival Results of Datopotamab Deruxtecan in Metastatic HR-Positive, HER2 Low/Negative Breast Cancer from TROPION-Breast01 Phase 3 Trial Announced.

UCB reveals that BIMZELX[®] (bimekizumab-bkzx) has been approved by the U.S. FDA for treating psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.

Henlius and Intas get Positive CHMP Opinion for HETRONIFLY® (marketed as HANSIZHUANG in China) in Europe for first-line treatment in adults with extensive-stage small cell lung cancer.

Ipsen's Iqirvo® (elafibranor) receives European Union approval as the first new therapy for primary biliary cholangitis in almost ten years.

The European Commission Approves Astellas' VYLOY™ (zolbetuximab) with Chemotherapy for Advanced Stomach and Gastroesophageal Junction Cancer.